Solu Therapeutics Debuts With $31 Million In Seed Funding To Unlock Antibody-Intractable Cell Surface Targets
Round Type
Seed
BostonBiotechnologyHealth CareTherapeuticsInvestors
Description
Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, founded by Longwood Fund, today announced the closing of an oversubscribed $31 million seed financing co-led by Longwood and Santé Ventures, with additional participation from DCVC Bio, Astellas Venture Management, and Alexandria Venture Investments. The proceeds will be used to leverage and develop the proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates which were in-licensed from GSK by the Company. This platform is designed to unlock antibody-intractable cell surface targets and build next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.
Quick answer
Solu Therapeutics raised an undisclosed amount in a Seed round, dated August 1, 2023. Investors: Peter Hutt, Satoshi Konagai, John Hamer, Ph.D., Managing Director, Dcvc Bio, Omar Khalil, Partner, Santé Ventures, Longwood Fund, Christoph Westphal, M.D., Ph.D., Founding Executive Chairman, Solu Therapeutics, Gsk and Alexandria Venture Investments. Solu Therapeutics is based in Boston, Massachusetts, United States.
- How much did Solu Therapeutics raise?
- Solu Therapeutics raised an undisclosed amount in a Seed round on August 1, 2023.
- Who invested in Solu Therapeutics?
- Peter Hutt, Satoshi Konagai, John Hamer, Ph.D., Managing Director, Dcvc Bio, Omar Khalil, Partner, Santé Ventures, Longwood Fund, Christoph Westphal, M.D., Ph.D., Founding Executive Chairman, Solu Therapeutics, Gsk and Alexandria Venture Investments are named as investors in this round.
- What does Solu Therapeutics do?
- Solu Therapeutics, a precision-medicine company, is developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity.
- Where is Solu Therapeutics based and how big is it?
- Solu Therapeutics is based in Boston, Massachusetts, United States.
- Who are the decision-makers at Solu Therapeutics?
- Fundz holds 1 contact at Solu Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Solu Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- DalCor Pharmaceuticals raised $80M (Series D) on September 13, 2023.
- Renibus Therapeutics raised an undisclosed amount (Series B) on September 12, 2023.
- Grit Biotechnology raised $60M (Series B) on September 8, 2023.
- Corteria raised $70M (Funding Round) on September 7, 2023.
- Rejuvenation Technologies raised $11M (Seed) on September 6, 2023.
- Nimbus Therapeutics raised $210M (Funding Round) on September 6, 2023.
Who to call at Solu Therapeutics, and when
A new round usually means Solu Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Solu Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Solu Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Solu Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Solu Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Solu Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.